RxDoctor Payments Data

Laszlo Tekler, DO

Cardiovascular Disease · Duluth, MNNPI 1184674277

Payments from drug & device makers

$269in general payments, 2019–2025

Across 14 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$87
  • Pfizer$39
  • Sanofi-aventis U.S. LLC$32
  • Merck$23
  • Bardy Diagnostics, Inc.$21
  • Boehringer Ingelheim$20
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.5$87
Pfizer2$39
Sanofi-aventis U.S. LLC1$32
Merck1$23
Bardy Diagnostics, Inc.1$21
Boehringer Ingelheim1$20
AstraZeneca1$17
Abbott1$15
Novartis1$15

How this compares

$269 in reported general payments places this provider in the 30th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$27,125
Medicare patients
278
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$80,071
XareltoRivaroxaban64$53,333
JardianceEmpagliflozin34$33,775
Repatha SureclickEvolocumab31$17,890
BrilintaTicagrelor18$14,210
Praluent PenAlirocumab14$7,062
Metoprolol Succinate176$2,526
Atorvastatin Calcium90$1,185
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$685
Ezetimibe50$657
Amlodipine Besylate108$609
ClopidogrelClopidogrel Bisulfate57$561
Rosuvastatin Calcium56$552
Losartan Potassium65$448
Isosorbide Mononitrate ErIsosorbide Mononitrate35$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$80,07187 claims
Boehringer IngelheimJardiance$20$33,77534 claims
AstraZenecaBrilinta$17$14,21018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →